Patients with ovarian cancer who are responsive to platinum-based chemotherapy may experience more than double an increase in PFS with a specific maintenance therapy, regardless of their disease characterization.
Researchers have identified follow-up care and outcomes disparities for patients with brain metastasis treated with stereotactic radiosurgery in a private hospital compared with those treated in a safety-net hospital.
A recent study investigated the drug utilization, health care resource utilization, and disease-related costs among patients with metastatic bladder cancer.
Patients with high-risk prostate cancer initiating long-term hormone therapy will likely benefit from two new treatments with comparable efficacy and safety profiles.
Scientists are stepping up the hunt for better diagnostic tests to predict if cancer patients will benefit from costly modern immunotherapy drugs, which are transforming cancer care but remain a hit-and-miss affair.
An international expert group has issued consensus-based recommendations on the use of biosimilars for rheumatologic diseases, focusing on cost, extrapolation, and switching between bio-originators and biosimilars.
Bristol-Myers Squibb’s immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday.
Patients with advanced, EGFR-mutant non-small cell lung cancer live almost twice as long without disease progression after initial treatment with an EGFR inhibitor compared with standard of care tyrosine kinase inhibitor therapy.
Older men with prostate cancer are more likely to be treated with radiation when their doctors own radiation machines - even those who may be too old to benefit from the treatment.
Administration of a PARP inhibitor to patients with recurrent ovarian cancer after an initial response to platinum-based chemotherapy helps maintain quality of life during treatment.